B
Bassem M. Chehab
Researcher at University of Kansas
Publications - 34
Citations - 332
Bassem M. Chehab is an academic researcher from University of Kansas. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 7, co-authored 24 publications receiving 155 citations. Previous affiliations of Bassem M. Chehab include Kansas City University of Medicine and Biosciences & Via Christi Hospital.
Papers
More filters
Journal ArticleDOI
Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial.
Raj Makkar,Wen Cheng,Ron Waksman,Lowell F. Satler,Tarun Chakravarty,Mark Groh,William Abernethy,Mark J. Russo,Mark J. Russo,David Heimansohn,James B. Hermiller,Stephen G. Worthley,Bassem M. Chehab,Mark J. Cunningham,Ray V. Matthews,Ravi K. Ramana,Gerald Yong,Carlos E. Ruiz,Chunguang Chen,Federico M. Asch,Mamoo Nakamura,Hasan Jilaihawi,Rahul Sharma,Sung Han Yoon,Augusto D. Pichard,Samir R. Kapadia,Michael J. Reardon,Deepak L. Bhatt,Gregory P. Fontana +28 more
TL;DR: A prospective, multicentre, non-inferiority, randomised controlled trial of the self-expanding intra-annular Portico transcatheter aortic valve system compared with any commercially available valves on the basis of safety and efficacy up to 2 years after the procedure.
Journal ArticleDOI
The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert Panel.
Sripal Bangalore,Hiram G. Bezerra,David G. Rizik,Ehrin J. Armstrong,Bruce Samuels,Srihari S. Naidu,Cindy L. Grines,Malcolm T. Foster,James W. Choi,Barry D. Bertolet,Atman P. Shah,Rebecca Torguson,Surendra B Avula,John Wang,James P. Zidar,Aziz Maksoud,Arun Kalyanasundaram,Steven J. Yakubov,Bassem M. Chehab,Anthony Spaedy,Srini Potluri,Ronald P. Caputo,Ashok Kondur,Robert F Merritt,Amir Kaki,Ramon Quesada,Manish Parikh,Catalin Toma,Fadi Matar,Joseph DeGregorio,William J. Nicholson,Wayne B. Batchelor,Raghava Gollapudi,Ethan C Korngold,Riyaz Sumar,George S. Chrysant,Jun Li,John B. Gordon,Rajesh Dave,Guilherme F. Attizzani,Tom Stys,Osvaldo Gigliotti,Bruce E. Murphy,Stephen G. Ellis,Ron Waksman +44 more
TL;DR: The factors potentially implicated in the excess risks, including the scaffold consideration and deployment technique, are discussed and patient and lesion selection, implantation technique, and dual antiplatelet therapy considerations are outlined to potentially mitigate this excess risk with the first-generation thick strut Absorb scaffold.
Journal ArticleDOI
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation.
Roxana Mehran,Davide Cao,Dominick J. Angiolillo,Sripal Bangalore,Deepak L. Bhatt,Junbo Ge,James B. Hermiller,Raj Makkar,Franz-Josef Neumann,Shigeru Saito,Hector Picon,Ralph Toelg,Aziz Maksoud,Bassem M. Chehab,José M. de la Torre Hernández,Vijay Kunadian,Gennaro Sardella,Holger Thiele,Olivier Varenne,Pascal Vranckx,Stephan Windecker,Yujie Zhou,Mitchell W. Krucoff,Karine Ruster,Jin Wang,Marco Valgimigli,Xience,Xience Investigators +27 more
TL;DR: In this paper, the authors evaluated two abbreviated dual-antiplatelet therapy (DAPT) regimens in patients at high bleeding risk (HBR) undergoing percutaneous coronary interventi...
Journal ArticleDOI
Safety Profile of an Intra-Annular Self-Expanding Transcatheter Aortic Valve and Next-Generation Low-Profile Delivery System.
Gregory P. Fontana,Francesco Bedogni,Mark Groh,David Smith,Bassem M. Chehab,H. Edward Garrett,Gerald Yong,Stephen G. Worthley,Ganesh Manoharan,Antony Walton,James B. Hermiller,Gaurav Dhar,Ron Waksman,Ravi K. Ramana,Paul Mahoney,Federico M. Asch,Tarun Chakravarty,Hasan Jilaihawi,Raj Makkar +18 more
TL;DR: Portico valve implantation with the FlexNav DS was associated with an excellent safety profile at 30 days, and clinical outcomes and valve performance were assessed by an independent clinical events committee and an echocardiography core laboratory.
Journal ArticleDOI
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Marco Valgimigli,Davide Cao,Dominick J. Angiolillo,Sripal Bangalore,Deepak L. Bhatt,Junbo Ge,James B. Hermiller,Raj Makkar,Franz-Josef Neumann,Shigeru Saito,Hector Picon,Ralph Toelg,Aziz Maksoud,Bassem M. Chehab,James W. Choi,Gianluca Campo,José M. de la Torre Hernández,Vijay Kunadian,Gennaro Sardella,Holger Thiele,Olivier Varenne,Pascal Vranckx,Stephan Windecker,Yujie Zhou,Mitchell W. Krucoff,Karine Ruster,Yan Zheng,Roxana Mehran,Xience,Xience Investigators +29 more
TL;DR: In this article, the optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown.